Elevated urinary glycosaminoglycans in Staphylococcus aureus bacteraemia with endovascular source
Journal of Medical Microbiology · 21.05.2026 · 75 (5)
DOI: 10.1099/jmm.0.002169 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Microbiology, erschienen am 21.05.2026. Verfasst von Dan F Smelter und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, University of Texas at Austin, Austin, TX, USA. Hauptthemen laut MEDLINE: Bacteremia, Staphylococcal Infections, Staphylococcus aureus, Glycosaminoglycans. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Society for Infectious Disease Pharmacists Early Career Research Grant, National Institute on Aging, Provost Early Career Fellows program at the University of Texas at Austin College of Pharmacy.
Abstract (Originalsprache)
The differentiation of endovascular sources of Staphylococcus aureus bacteraemia from non-endovascular infection carries significant prognostic information that can be used to therapeutically stratify patients. The endovascular glycocalyx is a protective barrier composed of glycosaminoglycans (GAGs) that can be degraded and excreted in the urine from endothelial injury occurring in endovascular infections, but not in non-endovascular infections. To determine whether patients who had S. aureus endovascular infections, including endocarditis, had increased urinary glycocalyx shedding suggestive of endothelial damage, urine samples from 55 patients with bacteraemia caused by S. aureus were assessed for GAG content. Patients with endovascular source bacteraemia were compared to those from non-vascular source bacteraemia (e.g. prosthetic joint infections, pyomyositis and cellulitis) for GAG content. As expected, patients with S. aureus bacteraemia stemming from endovascular foci of infection showed increased GAG content in the urine (24.11±4.9 g GAG/mol creatinine, n =22) compared to those with non-vascular infections (13.65±1.6 g GAG/mol creatinine, n =33, P =0.024). Further analysis of GAG composition in urine revealed differential presence of GAGs between these two groups. In the first pilot study of its kind, we found that the measurement of GAG in the urine of patients with S. aureus bacteraemia shows promise for clinical risk stratification to identify high-risk endovascular infections in order to guide clinical diagnostic and therapeutic decision-making. Larger studies will be needed to determine relevant quantitative cut-off values.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, University of Texas at Austin, Austin, TX, USA.
- Department of Medicine, UT San Antonio, San Antonio, TX, USA.
- School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA.
- Department of Pharmacy, UW Health, Madison, WI, USA.
- Sharp Rees Stealy Medical Group, San Diego, CA, USA.
- School of Medicine, University of California San Diego, La Jolla, CA, USA.
Förderung
- The Society for Infectious Disease Pharmacists Early Career Research Grant
- National Institute on Aging
- Provost Early Career Fellows program at the University of Texas at Austin College of Pharmacy
Zitieren
APA
Smelter, D. F., Volk, C. F., Gandhi, R., Sakoulas, G., & Rose, W. E. (2026). Elevated urinary glycosaminoglycans in Staphylococcus aureus bacteraemia with endovascular source. Journal of Medical Microbiology, 75(5). https://doi.org/10.1099/jmm.0.002169
Vancouver
Smelter DF, Volk CF, Gandhi R, Sakoulas G, Rose WE. Elevated urinary glycosaminoglycans in Staphylococcus aureus bacteraemia with endovascular source. Journal of Medical Microbiology. 2026;75(5). doi:10.1099/jmm.0.002169
BibTeX
@article{Smelter2026,
author = {Smelter, Dan F and Volk, Cecilia F and Gandhi, Ravi and Sakoulas, George and Rose, Warren E},
title = {Elevated urinary glycosaminoglycans in Staphylococcus aureus bacteraemia with endovascular source},
journal = {Journal of Medical Microbiology},
year = {2026},
volume = {75},
number = {5},
doi = {10.1099/jmm.0.002169}
}
EUVIMED